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Abstract
Background: Currently, about 2 per 1000 children in the industrialised world are severely visually impaired or blind
(SVI/BL) due to diverse uncommon conditions that are usually present from early infancy. The impact of SVI/BL is
lifelong and life-changing. Thus, children are a priority in the WHO-led global initiative against avoidable blindness.
The aim of this scoping review is to assess the current evidence base on interventions to prevent or treat the major
causes of childhood SVI/BL, specifically the degree of alignment between robust interventional research (RCTs) and
the burden (relative frequency) of the key causative disorders, identifying gaps in the evidence base for tackling
childhood blindness.
Methods/design: We will perform a scoping review of the published literature of randomised controlled trials
(RCTs) for clinical interventions that prevent or treat eye and vision diseases in children (<18 years old). Major
electronic databases MEDLINE (PUBMED), EMBASE and the Cochrane CENTRAL will be searched to identify
published trials using a comprehensive paediatric specific strategy informed by previous searches. The
outcome of our study, randomised clinical trial activity, will be measured by the total number of RCTs and
total paediatric participants randomised. The quantity and distribution of activity across diseases will be
classified in the broad categories of anatomical site affected (per WHO taxonomy). The degree of alignment
between paediatric trial activity and burden of SVI/BL disease (relative proportion) will be measured using a
test of association (Spearman’s correlation coefficient).
Discussion: Despite the global public health importance of childhood blindness, there has been no assessment of the
completeness of the evidence base regarding clinical interventions to prevent or treat the causative disorders. This
scoping review will measure the degree of alignment between the published evidence and the burden of disease to
identify gaps in current knowledge and consider the underlying reasons, informing clinicians, policy makers and
funders about research priorities.
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Background
The importance of paediatric eye disease
Paediatric eye and vision disorders are common, but
most are self-limiting or are easily fully addressed (e.g.
spectacles for refractive error) or amenable to good vis-
ual outcomes after treatment: for example, amblyopia
(“lazy eye”) affecting one eye occurs in between 1 and
7% of young children [1–7], and good improvements in
vision are achievable with treatment. In contrast, visual
impairment (VI) and severe visual impairment/blindness
(SVI/BL) are uncommon in the industrialised world af-
fecting about 2 per 1000 children, usually from birth or
infancy. VI and SVI/BL confers lifelong and life-
changing consequences for affected individuals, their
families and the societies in which they live, for example,
through the significant impact on development and
learning [8–10].
The global burden of disease is conventionally mea-
sured using DALYs (disability-adjusted life years), but
the lack of data on children, reflecting a paucity of na-
tional epidemiological studies of visual impairment [11],
means the burden of childhood blindness has to be in-
ferred from the YLD (years lived with disability) compo-
nent of DALYs, which is higher compared to adults,
because it occurs so much earlier (on average 7 decades
earlier) in the life course. Thus, children are a priority in
VISION 2020, the WHO-led global initiative against
avoidable blindness [8, 12].
Severe visual impairment/ blindness (SVI/BL) in chil-
dren is caused by a heterogeneous group of disorders
which are individually uncommon. From the only na-
tional epidemiological study of incident childhood SVI/
BL, which was carried out in the UK in 2000, it is esti-
mated that in high-income countries, 4 in 10,000 chil-
dren will become severely visually impaired or blind
before their first birthday, with that number increasing
to 6 in 10,000 before the age of 16 [9]; from that study,
the relative frequency of different underlying disorders
causing SVI/BL is known. Directly comparable informa-
tion for middle- and low-income settings are not avail-
able, but other studies indicate a significantly greater
rate and a very different pattern of causes [10]. Findings
from an on-going national study of childhood visual im-
pairment (VI) as well as SVI/BL, i.e. full spectrum visual
disability (acuity 0.5 LogMAR or worse in the better eye)
in the UK, will provide data on incidence and the
current pattern of causes [13].
Despite the global public health importance of child-
hood blindness, there has not yet been a study that maps
the completeness or coverage of the current evidence
base on interventions to prevent or treat the major
causes of childhood SVI/BL. The aim of this scoping re-
view is to measure the distribution of robust interven-
tional research (RCTs) across paediatric eye disease and
to determine the association between the quantity of
good quality RCTs and the burden of disease (relative
frequency) of the key causative disorders, identifying
gaps in the evidence base for tackling childhood blind-
ness and considering the reasons for this, so as to inform
research strategies and priorities.
The review will address the following questions in re-
lation to eye and vision disease in children:
1. How many randomised controlled trials in children
have been published and how many children/young
people have participated?
2. What is the distribution of research activity (the
‘quantity’ of RCT evidence) by disease,
distinguishing disorders associated with SVI/BL
from those that do not cause visual impairment?
3. What is the distribution of research activity by
disease as classified by anatomical site affected and
sub-classified by disorder
4. How does the distribution of research activity by
disease correlate with burden of childhood SVI/BL,
as classified by comparative incidence of SVI/BL by
anatomical site affected?
5. What are the gaps in our knowledge base in terms
of interventions for childhood vision and eye
disease?
Methods
Study design
This scoping review followed the framework outlined by
Arksey and O’Malley [14] and also adopted the updated
recommendations by Levac and colleagues for scoping
of the literature [15, 16]. In addition, this review will in-
corporate an evidence map to provide a user-friendly
format to illustrate the evidence gaps that exist in terms
of interventions to address severe visual impairment and
blindness in children. To ensure that the evidence map
produced is useful and easily interpretable to stake-
holders, the framework suggested by Bragge and col-
leagues produced for the global evidence mapping
initiative was followed [17, 18].
Our scoping review protocol will use a systematic ap-
proach to searching the literature for randomised con-
trolled trials in the broad topic area of interventions to
prevent or treat paediatric eye disease. The PRISMA-P
and PRISMA-PC statements were used to guide the
reporting of this protocol [19–21]. The populated
PRISMA-P checklist is available as a supplementary file
to this protocol (Additional file 1). In addition to
descriptive data extracted from each trial regarding the
disease investigated, intervention type and type of out-
come measures, we will focus on two key data points:
the number (quantity) of trials (per disease) and the
number of children/young people randomised. These
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two indicators of clinical research activity will be mapped
to the burden of disease for each blinding condition in
order to understand the distribution of robust evidence
across the breadth of paediatric eye disease.
Eligibility criteria
The following inclusion criteria will be used to guide the
search and will form the basis of the inclusion criteria at
the title and abstract level:
Participants: any trials where children (of 0 to 18 years
of age, in line with Article 1 of the United Nations Con-
vention on the Rights of the Child [22]) comprise the
total or majority of the study population. This was de-
fined as a trial that included exclusively participants aged
within 0–18 years or had a mean or median age of <
18 years if the trial included adult participants. Aside
from age, there were no further restrictions on charac-
teristics such as gender or ethnicity of participants.
Types of studies: Only randomised controlled trials
reporting results will be included. Quasi-RCTs will be
excluded. Protocols for randomised controlled trials will
be excluded. There will be no restriction with regards to
the date of publication, country context of the trials, lan-
guage or publication status.
Search strategy
In order to maintain sufficient breadth in our search to
capture all eye and vision disorders, we will use general
search terms (such as the MeSH terms ‘Eye diseases’ and
‘Eye’) to cover all major indexed eye conditions. As these
terms are automatically exploded in MEDLINE, it is
deemed broad enough to include all ophthalmic condi-
tions of interest. RCTs of conditions that are not associ-
ated with bilateral visual impairment (e.g. conjunctivitis,
blepharitis, amblyopia, squint) will be enumerated separ-
ately to provide context and scale for the RCT evidence
in relation to disorders that cause SVI/BL. We will limit
the scope of this search to include only randomised con-
trolled trials as this study focuses on the most robust
evidence from interventional research that is used to in-
form clinical decisions and policy making.
Preliminary searches were carried out and the strategy
refined after reviewing the relevance of preliminary re-
sults. One example of an adjustment to our search strat-
egy was in response to many studies that were included
as they mentioned RCTs in their abstracts but were not
themselves a randomised controlled trial in their study
design. In response to this finding, we removed the fol-
lowing publication types using the Boolean NOT term:
reviews, meta-analyses, practice guidelines, observational
studies, editorials, comments and letters. We also ad-
justed the paediatric filter within our search so that all
paediatric specific terms had to be present in the title or
abstract, after noting that many studies that do not
include children but includes participants 18 years and
over were indexed with the ‘Adolescent’ MeSH term (de-
fined by PUBMED as ages 13–18 years old).
Search methods
MEDLINE (PUBMED), EMBASE and CENTRAL in the
Cochrane Library will be searched for randomised con-
trolled trials reporting results. In order to maximise the
comprehensiveness of the search, there will be no re-
striction on date of publication. Paediatric search terms
created by authors will incorporate terms from the vali-
dated child filter for MEDLINE [23]. The MEDLINE
search strategy will be adapted to suit EMBASE (Ovid
interface). A second search will be carried out to target
trials addressing the cerebral causes of SVI/BL (known
as cerebral visual impairment or cortical visual impair-
ment (CVI)) that are not necessarily indexed as ‘eye dis-
ease’ and thus not captured in the first search. The CVI
search strategy has been developed in an iterative man-
ner, based on indexed search terms used in publications
of known trials measuring CVI as an outcome measure
(e.g. the Cool-cap trial [24]). This two-pronged search
strategy is illustrated in Fig. 1. The entire search strategy
is available as a supplementary file to this protocol (see
Additional file 2). Reference lists from eligible studies
will also be checked to ensure no pertinent trials are
missed.
Study selection
Records from all databases will be exported into and
managed in EndNote × 7 referencing software. Following
the removal of duplicates, eligibility assessment will be
Fig. 1 Proposed search strategy and screening process
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performed independently by two reviewers (LJT and
ALS). Double counting of trials will be avoided by syn-
thesising data from multiple reports using the trial regis-
tration number, where available, to identify unique trials.
The reason for trial exclusion will be recorded, e.g. not a
randomised trial (non-RCT), vision disorder not a pri-
mary disease of interest, or trial does not include chil-
dren. Any disagreement between reviewers will be
resolved by consensus. The senior author (JR) will hold
a determining vote if the consensus is not reached. Dual
data extraction for both clinical trial activity measures
will be carried out independently by LJT and ALS. Full
data extraction from trials will be carried out by LJT.
ALS will independently extract the full dataset from a
random sample of 33% of eligible trials. If there is
more than 10% disagreement on collected data, the
second reviewer (ALS) will extract the full dataset for
all eligible titles.
Risk of bias
Two reviewers (LJT and ALS) will independently assess
the methodological quality across eligible trials using the
Cochrane collaboration’s risk of bias tool for randomised
trials [25], which specifies six bias domains at the study
level that will be independently assessed by judgement
of both reviewers. The level of overall bias across the six
domains will be reported across trials as a low, unclear
or high risk of bias with support for the judgement pro-
vided as per the recommended list of items. Any dis-
agreement between authors over the risk of bias of a
particular publication will be resolved by discussion with
a third independent reviewer (senior author).
Classification of disorders
Disorders studied in RCTs will be classified as either po-
tentially causing SVI/BL or not independently by the au-
thors (LJT, ALS, JSR) and any disagreements resolved by
consensus.
Charting the data
Ten key data items will be extracted from eligible trials
and tabulated in a spreadsheet including one of the review
measures of clinical trial activity, i.e. the number of chil-
dren included in each trial (by disease). The list of items
extracted from each trial will also be presented collectively
in evidence tables, with trials categorized into one of eight
groups based on the anatomical site of injury: visual path-
ways and cortex; whole globe and anterior segment; cor-
nea, lens, uvea, retina, optic nerve, nystagmus and other.
The following data will be extracted from each eligible
trial:
1. Bibliometrics: Authors, publication year, title, journal
2. Type of RCT (if specified)
3. Method of randomisation
4. Sample size of paediatric participants randomised
5. Paediatric age range
6. Disease type (anatomical classification)
7. Intervention type (pharmacological, dietary
supplement, procedure, device or other) and
description
8. Comparator intervention
9. Primary ophthalmic outcome measure (or secondary
outcome measure for CVI trials)
10. Length of follow-up
Burden of paediatric eye disease
The relative frequency (%) of each disorder causing SVI/
BL in children (based on the annual incidence as re-
ported in the national surveillance study of SVI/BL in
the UK [9]) will be used as the proportional measure of
burden for each eye condition in the absence of global
burden of disease data in children. RCTs will be grouped
according to the primary anatomical site affected (e.g.
retina for retinopathy of prematurity) in order to assess
the distribution of evidence across all SVI/BL diseases,
as per the WHO taxonomy for causes of childhood
blindness.
Collating, summarising and reporting the results
The extent of the evidence from RCTs for each disorder
that causes SVI/BL will be measured in two ways: the
total number of RCTs involving children/young people
and total number of paediatric participants randomised.
Histograms will be used to plot these two measures of
clinical trial activity grouped by anatomical site. Scatter
plots will present total number of RCTs and total paedi-
atric participants (clinical trial activity) by the burden
(relative frequency of disease). The degree of alignment
between trial activity and burden which will be mea-
sured using an appropriate test of association will be
carried out and reported (Spearman’s correlation
coefficient).
Evidence map
A bubble chart will be used to present visually the quan-
tity of trial evidence (total RCTs) mapped against the
burden of disease (relative frequency of disease), with
the size of each bubble proportional to the total number
of paediatric participants. Each bubble will be coded to
identify the anatomical site affected.
Discussion
The intensity and focus of randomised trial research
should ideally align with the global burden of disease.
Measuring this association is important, as clinicians,
funding bodies and policy makers should be aware of
the areas where evidence is lacking in order to actively
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adjust research priorities. Children with SVI/BL are a
clinically heterogeneous population and require targeted
research to cover the many and multiple disorders that
lead to early visual impairment or blindness.
A poor association has been reported between the
quantity of randomised controlled trials and the global
burden of disease [26], specifically with only a moderate
association reported for RCT activity in paediatrics and
child health [27]. No study has investigated this question
of the association between the quantity and distribution
of RCT evidence on interventions and the burden of dis-
orders that cause visual disability. Therefore, the unique
aim of this scoping review is to ascertain whether rando-
mised trials of interventions to prevent or treat eye and
vision disorders that cause SVI/BL in children actually
reflect the burden of disease in industrialised countries
for whom the necessary data on burden of disease are
available.
We will use the findings of this review to highlight any
mismatch between the burden of childhood eye diseases
and the evidence, focusing specifically on the blinding
disorders that confer the highest impact. In identifying
these gaps in our knowledge with regards to interven-
tions, we will also discuss the potential barriers that have
led to this disparity. Additionally, this review will pro-
vide a unique summary of all the interventions and vis-
ual outcome measures used in RCTs in all ophthalmic
disorders in childhood, including common conditions
that do not confer visual impairment.
Additional files
Additional file 1: The guidelines outlined in the PRISMA-P checklist were
followed for this protocol, and the location of each point is illustrated in the
attached table in Additional file 1. (DOCX 32 kb)
Additional file 2: A complete list of search terms used for search in all
literature databases including PUBMED, EMBASE and Cochrane CENTRAL
is included in Additional file 2. (PDF 255 kb)
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